Shikari® (Q-RAV) Ravulizumab ELISA

This kit has been especially developed for the quantitative determination of Ravulizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Ravulizumab Drug Bank Accession Number is DB11580
Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking terminal complement-mediated inflammation, cell activation, and cell lysis in blood disorders associated with the destruction of red blood cells, thrombosis, and impaired bone marrow function. Complement system activation plays an important role in innate and acquired immunity. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.